TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00162149

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Nevirapine
Description: Tablets, Oral, 200 mg, Twice daily, 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine + Atazanavir/Ritonavir
Description: Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine + Atazanavir/Ritonavir
Description: Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atazanavir + Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
Study: NCT04550351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study: NCT03211429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai chi
Description: Tai Chi training in the Yang style of 24 movement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural control exercise
Description: Individually adjusted progressive and specific postural control training,
Study: NCT02262156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Description: Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned.
Study: NCT02311556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging
Study: NCT02921633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention letter
Study: NCT00941694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management intervention
Description: Intervention arm will receive 6 group or individual sessions over a 7 week period

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: 3 phone calls not related to asthma self-management
Study: NCT00540904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
Study: NCT02554552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3ml
Description: phosphate buffered saline 3ml
Study: NCT00931008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID530, Taxotere
Description: 75mg/m2
Study: NCT01368107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin 7
Description: patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin 7
Description: patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin 7
Description: patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
Study: NCT00901784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25mg Tablets
Study: NCT00931008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SID530, Taxotere
Description: 75mg/m2
Study: NCT04363853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 MG/ML
Description: We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
Study: NCT00979329

Intervention type: OTHER
Intervention: Questionnaires
Description: During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
Study: NCT03528109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
Study: NCT01059526

Intervention type: DRUG
Intervention: ecallantide
Description: 30 mg SC

Intervention type: DRUG
Intervention: ecallantide
Description: 30 mg SC
Study: NCT01318538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Women's Recovery Group
Description: The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Drug Counseling
Description: Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
Study: NCT02730000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART with Equia
Description: Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with Riva Self Cure
Description: Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
Study: NCT03471897

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycosaminoglycan plasma score
Description: A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycosaminoglycan plasma score
Description: A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
Study: NCT00901784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: 25mg Tablets
Study: NCT00684632

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246 (fentanyl citrate)
Description: KW-2246 (fentanyl citrate)
Study: NCT05296200

Intervention type: DEVICE
Intervention: Hyperbuoyancy Floatation
Description: Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
Study: NCT00382395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLX Gold Shunt GMS-plus
Description: Single use implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed FP7 Glaucoma Valve
Description: Single use implant
Study: NCT02624505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg Reference Product
Description: Drug: 90 mcg Reference Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 180 mcg Reference Product
Description: Drug: 180 mcg of Reference Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg Test Product
Description: Drug: 90 mcg of Test Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study: NCT06120114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified percutaneous internal ring suturing
Description: Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
Study: NCT00718484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifosfamide Tris and Doxorubicin
Description: On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
Study: NCT02484300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04505202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Description: The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
Study: NCT00463294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft with the use of CPB
Description: Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Graft without the use of CPB
Description: Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
Study: NCT02993354

Intervention type: DEVICE
Intervention: The EUM300 (electrical uterine myography)
Description: This study involves monitoring one group of pregnant women for contractions simultaneously using two different devices to determine if one is superior: the usual tocodynamometer commonly used. Women are simultaneously monitored with both devices.
Study: NCT03679468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: RehaCom software~Information processing speed and attention modules

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: RehaCom software~Information processing speed and attention modules

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Sets of balance and stretching exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Sets of balance and stretching exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Rehabilitation
Description: Kompozer software~24 session module consisting of basic internet searches

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Rehabilitation
Description: Kompozer software~24 session module consisting of basic internet searches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Recumbent NuStep Bike~Aerobic cycling

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic Exercise
Description: Recumbent NuStep Bike~Aerobic cycling
Study: NCT00547183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
Study: NCT02716857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone extended-release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of oxycodone extended-release
Study: NCT01593436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness training
Description: mindfulness interventions for 8 weeks for a group of menopausal insomniacs
Study: NCT01086332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: 1250 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
Study: NCT02172950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Description: Recombinant single-chain coagulation factor VIII

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Description: Recombinant single-chain coagulation factor VIII
Study: NCT00496626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
Description: Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
Study: NCT03165578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Feedback
Description: Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
Study: NCT03442140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmonica playing
Description: Patients will play the harmonica for up to 6 months
Study: NCT01487902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No ADT
Description: Docetaxel-prednisolone (TAX327 regimen) alone
Study: NCT02795715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Study: NCT01525641

Intervention type: DRUG
Intervention: Mirapex LA
Description: Pramipexole Hydrochloride Hydrate
Study: NCT00210964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole plus placebo
Description: ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid plus ceftazidime
Description: linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
Study: NCT00582959

Intervention type: OTHER
Group type: OTHER
Intervention: Cone Beam Imaging
Description: Prototype, third generation EPID based portal imaging system utilizing the MV approach.
Study: NCT00392886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Given on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Given on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Given on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Given on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Given on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Given on day 0

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
Study: NCT03781947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA
Description: A single s.c. or i.m. injection of teverelix TFA administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA
Description: A single s.c. or i.m. injection of teverelix TFA administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA
Description: A single s.c. or i.m. injection of teverelix TFA administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA
Description: A single s.c. or i.m. injection of teverelix TFA administered on Day 1
Study: NCT01193062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg